TOTAL: $550.14M
 
Company Location Date Amt. (M) Details
 
Accumetrics Inc. San Diego 10/6 $16.5 Accumetrics completed a round to raise $16.5M from existing investors, including Arnerich Massena, BBT Fund/Apothecary Capital, Essex Woodlands Health Ventures, Kaiser Permanente Ventures and RiverVest Venture Partners
 
Adimab Inc. Lebanon, N.H. 10/1 ND Adimab raised an undisclosed amount of money in its Series D financing round led by Google Ventures and included Polaris Ventures, SV Life Sciences, OrbiMed Advisors and Borealis Ventures
 
Arginetix Inc. Baltimore 10/2 $10.75 Arginetix closed a $10.75M Series A financing co-led by Quaker BioVentures and MedImmune Ventures; other investors were Maryland Health  Care Product Development Corp., Osage University Partners, Red Abbey Venture Partners  and company co-founder Acifophil LLC
 
 
Axcentua Pharmaceuticals AB Huddinge, Sweden 10/8 ND Axcentua closed its Series A round led by William Gunnarsson, former CEO and co-founder of Orphan Europe
 
Bellicum Pharmaceuticals Inc. Houston 10/27 $4.5 Bellicum raised $4.5M in a Series A and convertible note funding
 
Bicycle Therapeutics Ltd. London 10/6 ND Bicycle secured seed funding from Atlas Venture and Novartis Venture Fund
 
Biocartis SA Lausanne, Switzerland 10/15 $14.9 Biocartis raised about $14.9M in a Series A round from a syndicate of life science investors led by Aescap Venture
 
CBio Ltd. Brisbane, Australia 10/9 A$10 ($9) CBio completed a $9M financing ahead of a planned share market listing on the Australian Stock Exchange; it was underwritten by Novus Capital Ltd., which acted as financial advisor
 
Celtic Therapeutics Holdings LP St. Thomas, U.S. Virgin Islands 10/28 $100 PPD Inc. signed an agreement to invest $100M in Celtic
 
Crescendo Biologics Ltd. Cambridge, Mass. 10/12 £4.5 ($7.12) Crescendo raised $7.12M in a seed-funding round led by Sofinnova Partners
 
Endocyte Inc. West LaFayette, Ind. 10/15 $26 Completed a $26M extension of its Series C financing, including investments from Sanderling Ventures, Burrill & Co., American Bailey Ventures, Blue Chip Venture Co., and Triathlon Medical Ventures, as well as Clarian Health Ventures
 
Envoy Therapeutics Inc. Jupiter, Fla. 10/15 $8 Envoy Therapeutics raised $8M through a private placement of Series A preferred stock
 
Epizyme Inc. Cambridge, Mass. 10/7 $32 Epizyme raised $32M in a Series B round led by Bay City Capital, with new investments from Amgen Ventures and Astellas Venture Management and participation from existing investors MPM Capital and Kleiner Perkins Caufield and Byers
 
Evolva SA Basel, Switzerland 10/22 CHF28($27.8) Evolva completed a $27.8M Series B round as part of its move to merge with Arpida AG; investors were Aravis, Auriga Partners, Vinci Capital-Renaissance PME and Wellington Partners, as well as BioMedInvest, an undisclosed private investor, Astellas Venture, Dansk Innovation, Novartis Bioventures and Sunstone Capital
 
Flexion Therapeutics Woburn, Mass. 10/19 $33 Flexion completed a $33M Series A financing round
 
GlycoMimetics Gaithersburg, Md. 10/21 $38 GlycoMimetics raised $38M in the round, with investments from Genzyme Ventures, New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures
 
Inviragen LLC Fort Collins, Colo. 10/6 $15 Inviragen closed $15M in a Series A financing with investments from Charter Life Sciences, Bio*One Capital, Venture Investors LLC and Phillip Private Equity; it was done concurrently with the company's merger with SingVax Pte Ltd. of Singapore 
 
Integrated Diagnostics Seattle 10/14 $30 Integrated Diagnostics raised more than $30M in funding in a Series A led by InterWest Partners; other investors were the Wellcome Trust and dievini Hopp Biotech holding
 
Lux Biosciences Inc. Jersey City, N.J. 10/19 $50 Lux has raised $50M in a Series B round
 
Metabolon Inc. Research Triangle Park, N.C. 10/27 $6 Metabolon closed an additional $6M in its Series C financing round, bringing the total raised to $12.3M; investors were Syngenta Ventures, Fletcher Spaght Ventures, Sevin Rosen Funds, Aurora Funds, Harris and Harris Group, Fulcrum Financial Partners and Alexandria  Equities
 
Mission Bay Capital LLC San Francisco 10/27 $7.5 Mission Bay raised $7.5M in its first venture round
 
Mtm Laboratories AG Heidelberg, Germany 10/5 €7 ($10.3) Mtm brought in $10.3M in Series C funding; investors were Gilde Healthcare Partners, HBM BioVentures Ltd., HBM BioCapital Invest Ltd. and LBBW Venture Capital GmbH
 
OncoCyte Corp. Alameda, Calif. 10/16 $2 A private investor put $2M into OncoCyte, a new subsidiary of BioTime Inc.
 
PharmaDiagnostics NV Brussels, Belgium 10/12 €2.5 ($3.5) PharmaDiagnostics secured funding of $3.5M from its initial investors led by venture fund Capital-E
 
Pronota NV Ghent, Belgium 10/29 €1.3

($1.9)

Pronota raised an additional $1.9M in its Series B round, which was subscribed by MP Healthcare Venture Management Inc.
 
Synageva BioPharma Corp. Waltham, Mass. 10/20 $15 Synageva completed the final closing on a $45M financing that began earlier this year; $30M of the amount was accounted for in April
 
Tarsa Therapeutics Philadelphia 10/20 $24 Tarsa closed on a $24M Series A financing
 
Tetraphase Pharmaceuticals Inc. Watertown, Mass. 10/6 $10 Tetraphase closed the first $10M tranche of a $25M Series B round funded by Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures
 
Virdante Pharmaceuticals Inc. Cambridge, Mass. 10/29 $47 Virdante raised $47M in a Series A led by Thomas, McNerney & Partners with participation by Osage Partners and Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures
 
VitamFero Evry, France 10/8 €0.247 ($0.365) VitamFero completed its first round, with three founders bringing in $66,540 and 15 business angels from the Val de France Angels group adding $298,460
 
Notes:

Currency conversions are based on exchange rates at the time of the deal.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed.